Harrow Health ( (HROW) ) has released its Q3 earnings. Here is a breakdown of the information Harrow Health presented to its investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Harrow Inc. is a prominent North American pharmaceutical company specializing in the discovery and commercialization of innovative ophthalmic products, aimed at enhancing eyecare and making treatments more accessible and affordable.
In the third quarter of 2024, Harrow reported a significant revenue increase of 44% compared to the same quarter last year, reaching $49.3 million. Despite a GAAP net loss of $4.2 million, the company achieved an adjusted EBITDA of $8.8 million, showcasing continued operational strength.
Key financial highlights included a robust gross margin of 76% and an impressive rise in prescriptions for VEVYE, up 55% from the previous quarter. Additionally, Harrow marked its first major Medicare Part D win for VEVYE and announced new partnerships aimed at expanding access and affordability of its products.
Looking ahead, Harrow’s management remains optimistic, expecting to outperform its revenue guidance for the second half of 2024, driven by strong demand trends and operational efficiencies, setting the stage for a potentially record-breaking year.